Pt.2/2 Paradigm Shift - A WakeUp Call. Dark Secrets: Chemtrails, Genetics, Orbs Glowing Morgellons
A precarious substance in UFO sightings called #39;Angel Hair #39; is now frequently globally sighted as #39;Chemwebs. #39; Learn about its functions, purpose and relation to Morgellons fibers disease. Part...

By: nibirushock

Excerpt from:
Pt.2/2 Paradigm Shift - A WakeUp Call. Dark Secrets: Chemtrails, Genetics, Orbs & Glowing Morgellons - Video

Recommendation and review posted by Bethany Smith

The Role of Genetics in Clinical Trials | Memorial Sloan Kettering
Memorial Sloan Kettering experts discuss the role of genetics in clinical trials. Medical oncologist David Hyman discusses how using genetics can help match patients up to the best available...

By: Memorial Sloan Kettering

Read this article:
The Role of Genetics in Clinical Trials | Memorial Sloan Kettering - Video

Recommendation and review posted by Bethany Smith

Mr nice genetics
Nevilles haze in for the long run.

By: (RMC)rockymountaincultivators

See the original post:
Mr nice genetics - Video

Recommendation and review posted by Bethany Smith

Genetics Lesson 3 Chap 11

By: Tony Tolbert

View post:
Genetics Lesson 3 Chap 11 - Video

Recommendation and review posted by Bethany Smith

AP Bio - genetics review
Made with Explain Everything.

By: calderrama

Read more from the original source:
AP Bio - genetics review - Video

Recommendation and review posted by Bethany Smith

Davos 2015 - The end of Blindness
http://www.weforum.org/ A discussion with leading researchers on progress in the fight to end blindness by 2020 Dimensions to be addressed: - Mapping the brain to replicate vision - Stem...

By: World Economic Forum

See more here:
Davos 2015 - The end of Blindness - Video

Recommendation and review posted by Bethany Smith

DALLAS, February 2, 2015 /PRNewswire/ --

ReportsnReports.com adds Gene Therapy Respiratory Insight and Gene Therapy Immunology Insight market research reports on Pipeline Assessment, Market Trend, Technology and Competitive Landscape to its store.

The "Gene Therapy Immunology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape" industry research report provides in depth insights into the Immunology gene therapy. It has covered 10+ gene therapies covering 5+ Pharmaceutical companies. Studies are performed for approximately 10+ specific indications under Immunology. The Companies are utilizing 5 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 55% for viral vectors, 27% for RNAi therapeutics and 18% for Non Viral vectors. The Report is also giving early winners of the Immunology gene therapy market using a proprietary Matrix Model. Complete research is available at http://www.reportsnreports.com/reports/328010-gene-therapy-immunology-insight-pipeline-assessment-market-trend-technology-and-competitive-landscape.html .

The "Gene Therapy Respiratory Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape" market research report provides in depth insights into the Respiratory gene therapy. It has covered 5+ gene therapies covering 5+ Pharmaceutical companies. Studies are performed for approximately 5+ specific indications under Respiratory. The Companies are utilizing 5 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 22% for viral vectors, 22% for RNAi therapeutics and 56% for Non Viral vectors. The Report is also giving early winners of the Respiratory gene therapy market using a proprietary Matrix Model. Read more at http://www.reportsnreports.com/reports/328012-gene-therapy-respiratory-insight-pipeline-assessment-market-trend-technology-and-competitive-landscape.html .

These gene therapy market research reports provide the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The reports provide the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. Using propriety Competitive Matrix models, the reports also provide the first in class market analytics providing predictive analysis of early market winners of the clinical therapies and pre-clinical therapies in a demographic presentation view.

These reports provide a snapshot of the global Gene therapy market scenario, market trends & drivers, manacles of gene therapy; a review of the marketed Gene therapy products and marketing status; Coverage of global gene therapies under development across the globe covering territories; Competitive landscape of investigational products for key players and key therapy areas; covers the product description, stage of development, licensors & collaborators, Development partner and Technology information. The reports also provide the pre-clinical and clinical outcomes of the gene therapies. Each report has covered the vector used, target genes, localization of gene and detailed mechanism of action. They highlight the licensing opportunities and funding details for gene therapies as well as provide information of dormant and discontinued pipeline projects while covering market analytics of gene therapies using a propriety model.

On similar lines, the Gene Therapy Partnering Terms and Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the world's leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapy technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2009 including financial terms, where available, including over 250 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=262461 .

Go here to read the rest:
Immunology and Respiratory Gene Therapy Market Insights in New 2015 Research Reports

Recommendation and review posted by Bethany Smith

From wheelchair to Kilimanjaro in one year
January 23rd, 2014, I was in an accident where I crushed both my feet and broke my back after a fall from a climbing wall 12 meters high. The result was that I ended up in a wheelchair with...

By: inspiredh

See the rest here:
From wheelchair to Kilimanjaro in one year - Video

Recommendation and review posted by sam

Blue Skies the future of regenerative medicine
Dr. Stephen Minger, Chief Scientist of GE Healthcare Life Sciences, is one of the world #39;s leading experts on stem cells. In this London Futurists talk, he reviews the state of play with stem...

By: London Futurists

Go here to see the original:
Blue Skies the future of regenerative medicine - Video

Recommendation and review posted by sam

When money gets tight, research shows we may sacrifice our health in order to save $1 Two Canadian research centres are setting up a clinical trial to see if a type of stem cell can help alleviate symptoms of multiple sclerosis If you are spending time outdoors this winter, you do need to put on the sunscreen http://pmd.680news.com/podcasts/health/jan30-health-news_Health-Report_2015-02-02.mp3

See more here:
Jan. 30: Sacrificing health, multiple sclerosis research, sunscreen in winter

Recommendation and review posted by simmons

Source: Flickr user Dominik Golenia.

For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug developers and researchers. According to the National Institutes of Health, which has an annual budget near $40 billion, only $115 million is expected to be spent on MS research in 2015.

What makes MS a particularly scary disease -- beyond just its more serious complications like loss of vision and/or paralysis -- is that there are a number of unknowns even after decades of research. For example, scientists are still uncertain what causes MS, although they have a hunch it has to do with some combination of genetics and environmental factors, since the rate of MS prevalence above the 37th parallel is about to double what it is below the 37th parallel.

In recent years, MS diagnoses have been on the rise, although researchers simply attribute this to earlier diagnosis and better detection of the disease. MS can strike anyone at any age, but it's most often diagnosed when people are between the ages of 20 and 40.

Clearly, MS patients need help now, and not just in curbing their symptoms, but in actually finding ways to stop or reverse their disease. Thankfully, new research out of Northwestern University's Feinberg School of Medicine just might offer some game-changing and positive news.

Potentially game-changing news for select MS patients Based on a study published in the Journal of the American Medical Association by Dr. Richard Burt and his team at Northwestern University, utilizing nonmyeloablative hematopoietic stem cell transplantation resulted in substantial improvements in select MS patients' quality of life and neurological disability.

Source: Flickr user LWP Kommunikacio.

What's hematopoietic stem cell transplantation, or HSCT? It's the process whereby researchers harvest a user's own stem cells from their bone marrow or peripheral blood (stem cells can come from a donor as well), and subsequently infuse these potent stem cells back into the body in an effort to get an MS patients' immune system back onto the right track.

For its study, Northwestern University researchers examined 123 patients with relapse-remitting MS and 28 with secondary progressive MS who had been previously treated with HSCT. At a median of 30 months following treatment, researchers observed that 64% of those tested at the 48-month mark had demonstrated significant Expanded Disability Status Scale (EDSS) scores, as well as 50% of those tested at the 24-month mark. This marked the first true long-term and sustainable improvement in EDSS scores recorded in a clinical study involving MS.

Original post:
This Could Be Game-Changing News in the Battle Against Multiple Sclerosis

Recommendation and review posted by simmons

Could this experimental treatment reverse damage caused by a heart attack?

The heart muscle relies on a steady flow of oxygen-rich blood to nourish it and keep it pumping. During a heart attack, that blood flow is interrupted by a blockage in an artery. Without blood, the area of heart fed by the affected artery begins to die and scar tissue forms in the area. Over time, this damage can lead to heart failure, especially when one heart attack comes after another.

Though the heart is a tough organ, the damaged portions become unable to pump blood as efficiently as they once could. People who have had a heart attack therefore may face a lifetime of maintenance therapymedications and other treatments aimed at preventing another heart attack and helping the heart work more efficiently.

A new treatment using stem cellswhich have the potential to grow into a variety of heart cell typescould potentially repair and regenerate damaged heart tissue. In a study published last February in The Lancet, researchers treated 17 heart attack patients with an infusion of stem cells taken from their own hearts. A year after the procedure, the amount of scar tissue had shrunk by about 50%.

These results sound dramatic, but are they an indication that we're getting close to perfecting this therapy? "This is a field where, depending on which investigator you ask, you can get incredibly different answers," says Dr. Richard Lee, professor of medicine at Harvard Medical School and a leading expert on stem cell therapy.

"The field is young. Some studies show only modest or no improvement in heart function, but others have shown dramatically improved function," he says. "We're waiting to see if other doctors can also achieve really good results in other patients."

Studies are producing such varied outcomes in part because researchers are taking different approaches to harvesting and using stem cells. Some stem cells are taken from the bone marrow of donors, others from the patient's own heart. It's not clear which approach is the most promising.

Several different types of approaches are being used to repair damaged heart muscle with stem cells. The stem cells, which are often taken from bone marrow, may be inserted into the heart using a catheter. Once in place, stem cells help regenerate damaged heart tissue.

Like any other therapy, injecting stem cells into the heart can fail or cause side effects. If the stem cells are taken from an unrelated donor, the body's immune system may reject them. And if the injected cells can't communicate with the heart's finely tuned electrical system, they may produce dangerous heart rhythms (arrhythmias). So far, side effects haven't been a major issue, though, and that has encouraged investigators to push onward.

Read more here:
Repairing the heart with stem cells - Harvard Health ...

Recommendation and review posted by Bethany Smith

Dr. Brentjens on CAR T-Cell Therapy Challenges
Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Ch...

By: OncLiveTV

View post:
Dr. Brentjens on CAR T-Cell Therapy Challenges - Video

Recommendation and review posted by Bethany Smith

Devon Still -- Crucial Day For Leah ... Starts New Treatment This A.M.
Big day for Leah Still -- because her father told us the 4-year-old stars a new round of chemotherapy this morning that will hopefully crush her disease so badly, she can finally begin stem...

By: TMZSports

Read the original here:
Devon Still -- Crucial Day For Leah ... Starts New Treatment This A.M. - Video

Recommendation and review posted by Bethany Smith

Sioux Falls, S.D. (PRWEB) January 31, 2015

Sanford Health has selected a new leader for its research division. David Pearce, Ph.D., is the new president of Sanford Research.

Pearce replaces Gene Hoyme, M.D., who has transitioned to be Sanfords new chief of genetics and genomic medicine. Hoyme will also retain his positions as medical director of Sanford Imagenetics and chief academic officer for Sanford.

Dr. Pearce is an incredibly gifted and dedicated administrator and researcher who understands and believes in the vision of Sanford Research, said Rich Adcock, executive vice president for Sanford Health. He will manage a growing clinical and translational research portfolio and expanding programs in genetics and genomic research.

Pearce, who previously served as Sanford Researchs vice president and chief operating officer, now oversees research activities across Sanfords nine-state footprint, including more than 200 researchers, five research centers and more than 350 ongoing clinical trials. Sanford Research also maintains a working relationship with California-based Sanford Burnham Medical Research Institute and is a key collaborator with SAB Biotherapeutics Inc., a biopharmaceutical company located within the Sanford Research Center that has developed a unique technology platform to produce clinical-grade, fully human polyclonal antibodies to treat human diseases.

Pearce will maintain his role as director of the Childrens Health Research Center at Sanford Research and continue to run his lab, which is internationally regarded for its work with Batten disease, a group of pediatric neurodegenerative disorders he has studied for more than a decade.

As Sanford Researchs vice president and COO, Pearce led efforts to establish the Sanford BioBank, Edith Sanford Breast Cancer Research and a global rare disease registry. The BioBank is a collection of biological samples and general health information from thousands of people for use in future research studies, while Edith Sanford Breast Cancer Research explores customized prevention and treatment strategies for breast cancer using the latest in genomic medicine.

Sanford Research is uniquely positioned to provide translational research that can bring important discoveries from bench to bedside, improving the quality of care Sanford Health provides, said Pearce. Whether it is being a national leader in head and neck cancer survival rates or bringing innovative medical devices to market, Sanford Research is changing the landscape of health care.

Prior to joining Sanford Research in 2009, Pearce was a researcher and associate professor at the University of Rochester (N.Y.). A native of the United Kingdom, he graduated from Wolverhampton Polytechnic and has a doctorate in biochemistry from the University of Bath. Pearce also did postdoctoral work at the University of Rochester and Oxford University.

About Sanford Research Sanford Research is a non-profit research organization and is part of Sanford Health, an integrated health system headquartered in the Dakotas. Sanford represents the largest, rural, not-for-profit health care system in the nation with a presence in 111 communities, nine states and two countries. In 2007, a transformational gift of $400 million by Denny Sanford provided for an expansion of childrens and research initiatives, one of which was to find a cure for type 1 diabetes, and has given Sanford Research significant momentum in its goal of becoming one of the premiere research institutions in the United States and the world. Most recently, subsequent gifts of more than $200 million by Mr. Sanford have paved the way to establish Edith Sanford Breast Cancer Research and Sanford Imagenetics.

See the original post here:
Sanford Research Names New President

Recommendation and review posted by Bethany Smith

MENAFN - Al-Anbaa - 01/02/2015 (MENAFN - Al-Anbaa) The United States has proposed analyzing genetic information from more than 1 million American volunteers as part of a new initiative to understand human disease and develop medicines targeted to an individual's genetic make-up. At the heart of the "precision medicine" initiative, announced on Friday by President Barack Obama, is the creation of a pool of people - healthy and ill, men and women, old and young - who would be studied to learn how genetic variants affect health and disease.

Officials hope genetic data from several hundred thousand participants in ongoing genetic studies would be used and other volunteers recruited to reach the 1 million total.

"Precision medicine gives us one of the greatest opportunities for new medical breakthroughs we've ever seen," Obama said, promising that it would "lay a foundation for a new era of life-saving discoveries."

The near-term goal is to create more and better treatments for cancer, Dr. Francis Collins, director of the National Institutes of Health (NIH), told reporters on a conference call on Thursday. Longer term, he said, the project would provide information on how to individualize treatment for a range of diseases.

The initial focus on cancer, he said, reflects the lethality of the disease and the significant advances against cancer that precision medicine has already made, though more work is needed.

The effort may raise alarm bells for privacy rights advocates who have questioned the government's ability to guarantee that DNA information is kept anonymous.

Obama promised that "privacy will be built in from day one."

Read the original post:
U.S. to analyze DNA from 1 million people

Recommendation and review posted by Bethany Smith

Genetics test review
Genetics test review.

By: Angie Bio Teacher

Read the original post:
Genetics test review - Video

Recommendation and review posted by Bethany Smith

The Sims 3: Perfect Genetics - Part 11 - [The Genes!]
READ ME** In this part: THE PERFECT GENETICS?!?!!! Social Media: Facebook: http://www.facebook.com/MsGryphi Twitter: http://www.twitter.com/MsGryphi Tumblr...

By: MsGryphi

See the original post here:
The Sims 3: Perfect Genetics - Part 11 - [The Genes!] - Video

Recommendation and review posted by Bethany Smith

Minecraft Wars - Organics + Genetics Chamber! #43
Today I show you the new addition to the bunker where auto farming/genetics modification systems will be placed amongst other cool things and get to work on making it a reality. Get a Creeperhost...

By: Finbarhawkes

See original here:
Minecraft Wars - Organics + Genetics Chamber! #43 - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play: The Sims 3 Perfect Genetics Challenge (Part 7)- Fire
In this part we give Maddie and Megan new looks and Spencer starts a fire. Please Like, Share and Subscribe!

By: InstaSimmer

Read more:
Let's Play: The Sims 3 Perfect Genetics Challenge (Part 7)- Fire - Video

Recommendation and review posted by Bethany Smith

Advanced Genetics 1.7.2
This is the advanced genetics mod and the recipes will be on the minecraft Forum there are NO recipes in the video so if you are looking for recipes please find another video.

By: Pinky Purple 216

Go here to read the rest:
Advanced Genetics 1.7.2 - Video

Recommendation and review posted by Bethany Smith

Mower Genetics - 28.day flowering LAC/SAGE hybrids

By: Mower Genetics

The rest is here:
Mower Genetics - 28.day flowering LAC/SAGE hybrids - Video

Recommendation and review posted by Bethany Smith

Perfect Genetics Challenge - Vote for your heiress now.
Thumbs up if your excited!! 1. Please go to my website and vote for your fav girl to be our heiress! Vote Girl 1, Girl 2, Girl 3 or Girl 4 in the order i showed them today - http://xsimsug...

By: xSimSugar

Read more:
Perfect Genetics Challenge - Vote for your heiress now. - Video

Recommendation and review posted by Bethany Smith

To show your support of this position statement, please send an e-mail with your intent, and affiliation to danielle.bonadies@yale.edu

Below please find the full text on a Genetic Testing Lab Position Statement that pledges we, the ordering clinicians, will continue to make laboratory and testing choices based on what is in the best interest of our patients and will not be swayed by political, personal or financial gain.

This is also an opportune time for patient organizations, clinical organizations and insurers to show their support of laboratories that will fully share past, current and future data in open databases that serve research and patient care.

Please pass this on to your family, friends, colleagues, patients and contacts within your networks.

Genetic Testing Position Statement

Cancer Genetic Counseling Program Yale School of Medicine/Yale Cancer Center

New Haven, CT February 2014

With the emergence of new testing technologies and the 2013 Supreme Court decision banning gene patenting, the available cancer genetic testing options and the laboratories offering testing have expanded exponentially and are likely to continue to do so. As providers we have a responsibility to our patients to make the best decisions regarding which laboratory to use and which tests are most appropriate based on what is best for the patients. Our decisions will not be swayed by political, personal and/or financial gain.

2. Time: How long will the patient have to wait for his or her test results?

3. Cost: Will our patients insurance carrier cover this test at this laboratory?

Go here to read the rest:
Cancer Genetic Counseling

Recommendation and review posted by Bethany Smith

Albany, NY (PRWEB) February 01, 2015

The new report is titled Recombinant Coagulation Factors 2015: Maturation of Recombinant Clotting Factor Pipeline and Emergence of Gene Therapy and Alternative Procoagulants and deals with historical statistics and future projections regarding the recombinant coagulation factors market. It gathers data from 2013 and the first three quarters of 2014 to analyze the development of the market through the two years. It focuses strongly on pipeline products in the market.

To get sample report with TOC Click Here: http://www.researchmoz.com/enquiry.php?type=sample&repid=241916

Recombinant coagulation factors are used in diseases such as hemophilia A and B, to bring about blood coagulation when the patients natural capacity to do so has been hampered. Market data for various classes of recombinant coagulation factors such as factors VII, VIII, and IX are analyzed in the research report, along with an examination of the development of other nascent and comparatively untouched substances and methods such as alternative procoagulants, immune tolerance-inducing agents, and gene therapeutics.

The report profiles the competitive landscape in detail and provides special attention to the impact of new products on the respective positions of major players of the market. This helps gain insight into the short-to-mid-term future of the market. Trends gaining strength in the market are also carefully examined, according to their potential impact on the market stats and competitive landscape.

To Browse a Full Report with TOC: http://www.researchmoz.us/recombinant-coagulation-factors-2015-maturation-of-recombinant-clotting-factor-pipeline-and-emergence-of-gene-therapy-and-alternative-procoagulants-report.html

The field of gene therapeutics, or gene therapy, is a strong emergent alternative to recombinant coagulation factors. New technologies in the gene therapy field are examined in detail, as are the major players intending to strengthen their presence in this sector. Keeping with this theme, the competitive advantages of alternative procoagulants and gene therapy are listed and analyzed.

The sales and market size of four major types of recombinant coagulation factors are analyzed in the report: rFVIII, rFIX, rFVII, and thrombin. Within the market analysis of rFVIII, specific medicines such as Helixate, Kogenate, Advate/Recombinate, etc. are analyzed deeper to understand their particular market size data. Likewise, the market data for medicines such as Benefix and Alprolix, which constitute the recombinant factor IX category, and NovoSeven and Coagil VII, which make up the recombinant factor VII category, are also examined in detail. The recombinant factor Thrombin is analyzed as a separate category.

Among pipeline projects, two distinct classes can be formed: wild-type recombinant factors and long-acting recombinant factors. Research into all types of recombinant factors, i.e., rFVIII, rFIX, and rFVII is ongoing to produce wild and long-acting varieties of each. The present market conditions for each are also described in the report, giving a clear idea of the trajectory from the present market conditions to the pipeline projects.

The report also profiles major pharmaceutical companies active in the recombinant coagulants market. These include giants such as Baxter, CSL, Novo Nordisk, Bayer HealthCare Pharmaceuticals, Biogen Idec, AstraZeneca, etc.

Read the original post:
Recombinant Coagulation Factors Pipeline Analysis to 2015 Now Available on ResearchMoz

Recommendation and review posted by Bethany Smith